Quicksilver Scientific

Free ground shipping over $50 (excludes HI, AK, & PR)


Unsupported Browser

This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

EDTA References

  1. Fabbrizzi L. Living in a cage is a restricted privilege. Top Curr Chem. 2012;323:127-66. View Abstract
  2. Suh JH. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 2005;10(1):52-60. View Abstract
  3. Kartal SN. Removal of copper, chromium, and arsenic from CCA-C treated wood by EDTA extraction. Waste Management. 2003 Dec 31;23(6):537-46. View Abstract
  4. De Gregori I et al. Extractable copper, arsenic and antimony by EDTA solution from agricultural Chilean soils and its transfer to alfalfa plants (Medicago sativa L.). J Enviro Monitor 2004;6(1):38-47. View Full Paper
  5. Patrick L et al. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity.Altern Med Rev. 2002 Dec;7(6):456-71. View Full Paper
  6. Flora SJ et al. Heavy metal induced oxidative stress & its possible reversal by chelation therapy Indian J Med Res. 2008 Oct;128(4):501-23. View Abstract
  7. Ziegler EE et al. Absorption and retention of lead by infants. Pediatr Res. 1978 Jan; 12(1):29-34. View Article
  8. Jan AT et al. Heavy Metals and Human Health: Mechanistic Insight into Toxicity and Counter Defense System of Antioxidants. Int J Mol Sci. 2015;16(12):29592–29630 View Full Paper
  9. Flora S. Arsenic-induced oxidative stress and its reversibility. Free Radic. Biol. Med. 2011;51:257–281. View Abstract
  10. Ferrero ME. Rationale for the successful management of EDTA chelation therapy in human burden by toxic metals. Biomed Res Int. 2016;2016:8274504. View Full Paper
  11. Aheran GA et al. Mechanisms of heavy-metal sequestration and detoxification in crustaceans: a review.J Comp Physiol B. 2004 Aug;174(6):439-52. View Abstract
  12. Salehi B. Insights on the use of α-Lipoic acid for therapeutic purposes. Biomolecules. 2019 Aug 9;9(8). View Full Paper
  13. Seifar F. α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review. Nutr Neurosci. 2019 May;22(5):306-316. View Abstract
  14. Flora SJ et al. Chelation in metal intoxication. Int J Environ Res Public Health. 2010;7(7):2745–2788 View Full Paper
  15. Foreman H et al. The metabolism of C14 labeled ethylene diamino tetraacetic acid in human beings. J Lab Clin Med. 1954;43:566–571. [View Abstract]
  16. Andersen O. Principles and recent developments in chelation treatment of metal intoxication. Chem Rev. 1999 Sep 8;99(9):2683-710. View Full Paper
  17. Jonah MM et al. Tissue of EDTA encapsulated within liposomes of varying surface Biochim Biophys Acta. 1975 Sep 2;401(3):336-48 View Abstract
  18. Jonah MM et al. Tissue distribution of EDTA encapsulated within liposomes containing glycolipids or brain phospholipids. Biochim Biophys Acta. 1978 Jul 3;541(3):321-33. View Abstract
  19. Patrick L. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Altern Med Rev. 2002 Dec;7(6):456-71. View Full Paper
  20. Breithaupt-Grogler K et al. Dose-proportionality of oral thioctic acid–coincidence of assessments via pooled plasma and individual data. Eur J Pharm Sci. 1999;8(1):57-65.View Abstract
  21. Schelkonogov VA et al. Liposomal form of lipoic acid: preparation and determination of antiplatelet and antioxidant activity Biomed Khim. 2016 Jul;62(5):577-583. View Abstract
  22. Külkamp IC. J Biomed Nanoencapsulation improves the in vitro antioxidant activity of lipoic acid.
  23. 2011 Aug;7(4):598-607. View Abstract
  24. Cranton EM et al. Free oxygen radical pathology and EDTA chelation therapy: mechanisms of action. Journal of Advancement in Medicine. 1998;11(4):277–310. View Full Paper
  25. Miller KL et al. Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. Am Heart J. 2004 Mar; 147(3):401-11. View Abstract
  26. Roussel AM et al. EDTA chelation therapy, without added vitamin C, decreases oxidative DNA damage and lipid peroxidation.Altern Med Rev. 2009 Mar;14(1):56-61. View Abstract
  27. VE Kagan et al.Dihydrolipoic acid—a universal antioxidant both in the membrane and in the aqueous phase
  28. Biochem Pharmacol, 44 (1992), pp. 1637-1649 View Abstract
  29. Shay KP et al. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790:1149–1160. View Full Paper
  30. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. J Clin Biochem Nutr. 2015 Jul; 57(1): 21–26 View Abstract
  31. Goralska M et al. Alpha lipoic acid changes iron uptake and storage in lens epithelial cells. Exp. Eye Res. 2003, 76, 241–248. View Abstract
  32. Sun H et al. Alphalipoic Acid Prevents Oxidative Stress and Peripheral Neuropathy in Nab-Paclitaxel-Treated Rats through the Nrf2 Signalling Pathway. Oxid Med Cell Longev. 2019 Feb 10;2019:3142732. View Full Paper
  33. Rocamonde B et al. Neuroprotection of lipoic acid treatment promotes angiogenesis and reduces the glial scar formation after brain injury. Neuroscience2012;224:102–115. View Abstract
  34. Seifer F et al. α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review. Nutr Neurosci. 2019 May;22(5):306-316 View Abstract
  35. Sloth-Nielsen J et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg. 1991 Aug;162(2):122-5. View Abstract
  36. Lamas GA et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy.
  37. Am Heart J. 2014 Jul;168(1):37-44.e5. View Full Paper
  38. Chen KH et al. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens Am J Kidney Dis. 2012 Oct;60(4):530-8. View Abstract
  39. Zanella SG. Personalization of multiple sclerosis treatments: using the chelation therapy approach.Explore (NY). 2013 Jul-Aug;9(4):244-8. View Abstract
  40. Dinicola S et al. Alpha-Lipoic Acid downregulates IL-1 and IL-6 by DNA hypermethylation in SK-N-BE neuroblastoma cells. Antioxidant 2017, 6, 74. View Abstract
  41. Khalili M et al. Does lipoic acid consumption a_ect the cytokine profile in multiple sclerosis patients: A double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation 2014, 21, 291–296. View Abstract
  42. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med. 1995 Aug;19(2):227-50. View Abstract
  43. Bustamante J, Lodge JK, Marcocci L, et al. Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med. 1998 Apr;24(6):1023-39. View Abstract
  44. Gurer H, et al. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Radic Biol Med. 1999 Jul;27(1-2):75-81. View Abstract
  45. Spector AA et al. Membrane lipid composition and cellular function. J Lipid Res. 1985 Sep;26(9):1015-35 View Full Paper
  46. Porter CJ. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst. 1997;14(4):333-93 View Full Paper
  47. Ahn H, Park JH. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016 Nov 23;20:36 View Full Paper
  48. Alyautdin R et al. Nanoscale drug delivery systems and the blood brain barrier. Int J Nanomedicine. 2014 Feb 7;9:795-811 View Full Paper
Your Cart